The immune landscape of undifferentiated pleomorphic sarcoma.

Saved in:
Bibliographic Details
Title: The immune landscape of undifferentiated pleomorphic sarcoma.
Authors: Lazcano R; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Barreto CM; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Salazar R; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Carapeto F; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Traweek RS; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Leung CH; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gite S; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Mehta J; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ingram DR; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wani KM; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Vu KT; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Parra ER; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lu W; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zhou J; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Witt RG; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cope B; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Thirasastr P; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lin HY; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Scally CP; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Conley AP; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ratan R; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Livingston JA; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zarzour AM; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ludwig J; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Araujo D; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ravi V; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Patel S; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Benjamin R; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wargo J; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wistuba II; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States., Somaiah N; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Roland CL; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Keung EZ; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Solis L; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wang WL; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States., Lazar AJ; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nassif EF; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Oct 12; Vol. 12, pp. 1008484. Date of Electronic Publication: 2022 Oct 12 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2022.1008484